Structure

InChI Key DQCKKXVULJGBQN-XFWGSAIBSA-N
Smile O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
InChI
InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C20H23NO4
Molecular Weight 341.41
AlogP 1.53
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 2.0
Polar Surface Area 70.0
Molecular species BASE
Aromatic Rings 1.0
Heavy Atoms 25.0

Pharmacology

Action Mechanism of Action Reference
ANTAGONIST Opioid receptors; mu/kappa/delta antagonist DailyMed
Primary Target
δ receptor
κ receptor
μ receptor

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Alcoholism 4 D000437 ClinicalTrials
Endometriosis 3 D004715 ClinicalTrials
Obesity 3 D009765 ClinicalTrials
Pain 3 D010146 ClinicalTrials
Chronic Pain 3 D059350 ClinicalTrials
Gambling 3 D005715 ClinicalTrials
Opioid-Related Disorders 3 D009293 ClinicalTrials
Heroin Dependence 3 D006556 ClinicalTrials
Tobacco Use Disorder 3 D014029 ClinicalTrials
Multiple Sclerosis 3 D009103 ClinicalTrials
Cocaine-Related Disorders 3 D019970 ClinicalTrials
Substance-Related Disorders 3 D019966 ClinicalTrials
Depressive Disorder 3 D003866 ClinicalTrials
Depressive Disorder 3 D003866 ClinicalTrials
Opioid-Related Disorders 3 D009293 ClinicalTrials
Stress Disorders, Post-Traumatic 3 D013313 ClinicalTrials
HIV Infections 3 D015658 ClinicalTrials
Borderline Personality Disorder 3 D001883 ClinicalTrials
Low Back Pain 2 D017116 ClinicalTrials
Amphetamine-Related Disorders 2 D019969 ClinicalTrials
Crohn Disease 2 D003424 ClinicalTrials
Obsessive-Compulsive Disorder 2 D009771 ClinicalTrials
Colitis, Ulcerative 2 D003093 ClinicalTrials
Marijuana Abuse 2 D002189 ClinicalTrials
Dry Eye Syndromes 2 D015352 ClinicalTrials
Severe Acute Respiratory Syndrome 2 D045169 ClinicalTrials
Migraine Disorders 2 D008881 ClinicalTrials
Fibromyalgia 2 D005356 ClinicalTrials
Coronavirus Infections 2 D018352 ClinicalTrials
Respiratory Distress Syndrome 2 D012128 ClinicalTrials
Trichotillomania 2 D014256 ClinicalTrials
Depressive Disorder, Major 2 D003865 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Alcohol-Related Disorders 2 D019973 ClinicalTrials
Cystitis, Interstitial 2 D018856 ClinicalTrials
Diabetic Neuropathies 2 D003929 ClinicalTrials
Severe Acute Respiratory Syndrome 2 D045169 ClinicalTrials
Child Development Disorders, Pervasive 1 D002659 ClinicalTrials
Dermatitis, Atopic 1 D003876 ClinicalTrials
Psoriasis 1 D011565 ClinicalTrials
Schizophrenia 1 D012559 ClinicalTrials
Alcohol Drinking 1 D000428 ClinicalTrials
Bulimia 0 D002032 ClinicalTrials

Related Entries

MCS

Scaffolds

Salt

Side Effects from Label

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
26.13
Injury, poisoning and procedural complications
17.9
Psychiatric disorders
15.85
Nervous system disorders
8.99
Gastrointestinal disorders
5.79
Musculoskeletal and connective tissue disorders
4.31
Skin and subcutaneous tissue disorders
3.54
Respiratory, thoracic and mediastinal disorders
2.17
Investigations
2.07
Vascular disorders
2.04

Cross References

Resources Reference
CAS NUMBER 16590-41-3
ChEBI 7465
ChEMBL CHEMBL19019
DrugBank DB00704
DrugCentral 1765
EPA CompTox DTXSID4046313
FDA SRS 5S6W795CQM
Human Metabolome Database HMDB0014842
Guide to Pharmacology 1639
KEGG C07253
PharmGKB PA450588
PubChem 5360515
SureChEMBL SCHEMBL34681
ZINC ZINC000000001773